NASDAQ:HZNP - Horizon Therapeutics Public Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $119.89
  • Forecasted Upside: 6.32 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$112.76
▼ -0.19 (-0.17%)

This chart shows the closing price for HZNP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Horizon Therapeutics Public Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HZNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZNP

Analyst Price Target is $119.89
▲ +6.32% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $119.89, with a high forecast of $135.00 and a low forecast of $100.00. The average price target represents a 6.32% upside from the last price of $112.76.

This chart shows the closing price for HZNP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Horizon Therapeutics Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/19/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021Jefferies Financial GroupInitiated CoverageBuy$132.00Low
8/26/2021Morgan StanleyBoost Price TargetOverweight$103.00 ➝ $135.00Low
8/24/2021The Goldman Sachs GroupBoost Price TargetNeutral$96.00 ➝ $107.00Low
8/5/2021BMO Capital MarketsBoost Price TargetOutperform$118.00 ➝ $132.00Low
8/5/2021CitigroupBoost Price TargetBuy$117.00 ➝ $121.00Medium
5/27/2021Maxim GroupReiterated RatingReduceHigh
3/29/2021Morgan StanleyReiterated RatingOverweight$103.00High
3/25/2021GuggenheimBoost Price TargetBuy$115.00 ➝ $120.00Low
3/22/2021Morgan StanleyInitiated CoverageOverweight$103.00Medium
3/19/2021Jefferies Financial GroupReiterated RatingBuy$120.00Low
3/18/2021CitigroupBoost Price Target$116.00 ➝ $120.00High
3/17/2021Stifel NicolausBoost Price TargetBuy$110.00 ➝ $125.00High
3/11/2021Wolfe ResearchInitiated CoverageOutperform$107.00Low
2/17/2021Jefferies Financial GroupBoost Price Target$103.00 ➝ $120.00Low
2/9/2021Bank of AmericaReiterated RatingBuy$100.00Low
11/3/2020BMO Capital MarketsBoost Price TargetOutperform$105.00 ➝ $110.00Medium
9/9/2020JPMorgan Chase & Co.Initiated CoverageOverweight$110.00High
8/27/2020CitigroupInitiated CoverageBuy$112.00Medium
8/17/2020Bank of AmericaBoost Price TargetBuy$92.00 ➝ $95.00Low
8/10/2020Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $90.00Low
8/6/2020GuggenheimBoost Price Target$64.00 ➝ $100.00High
8/6/2020BMO Capital MarketsBoost Price TargetOutperform$70.00 ➝ $105.00High
8/3/2020Stifel NicolausBoost Price Target$60.00 ➝ $85.00Low
7/31/2020Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $70.00Low
7/22/2020Piper SandlerBoost Price TargetOverweight$61.00 ➝ $90.00Low
7/16/2020GuggenheimBoost Price Target$50.00 ➝ $64.00Low
6/5/2020Piper SandlerReiterated RatingBuy$61.00Medium
5/29/2020Stifel NicolausBoost Price Target$50.00 ➝ $60.00High
5/26/2020Bank of AmericaBoost Price TargetBuy$52.00 ➝ $57.00Medium
5/21/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $61.00Medium
5/8/2020Morgan StanleyBoost Price TargetOverweight$39.00 ➝ $50.00High
4/28/2020Jefferies Financial GroupBoost Price TargetBuy$47.00 ➝ $51.00High
4/14/2020Piper SandlerLower Price TargetOverweight$46.00 ➝ $44.00High
4/8/2020Stifel NicolausReiterated RatingBuy$45.00Low
4/2/2020Morgan StanleyLower Price TargetOverweight$42.00 ➝ $39.00High
3/23/2020Bank of AmericaLower Price TargetBuy$45.00 ➝ $42.00Low
2/25/2020Bank of AmericaReiterated RatingBuy$45.00High
1/22/2020BMO Capital MarketsBoost Price TargetOutperform$40.00 ➝ $46.00Low
1/14/2020JMP SecuritiesBoost Price TargetOutperform$47.00Medium
1/8/2020The Goldman Sachs GroupInitiated CoverageNeutral$35.00Low
12/24/2019Piper Jaffray CompaniesReiterated RatingBuy$36.00 ➝ $49.00Low
12/16/2019Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $38.00High
12/16/2019Jefferies Financial GroupBoost Price TargetBuy$35.00 ➝ $40.00High
12/16/2019Stifel NicolausBoost Price TargetBuy$35.00 ➝ $40.00High
12/16/2019BMO Capital MarketsBoost Price TargetOutperform$36.00 ➝ $40.00High
11/8/2019Cantor FitzgeraldBoost Price TargetOverweight$32.00 ➝ $36.00Low
9/26/2019Bank of AmericaInitiated CoverageBuy$34.00High
9/13/2019Stifel NicolausSet Price TargetBuy$35.00Low
9/12/2019GuggenheimInitiated CoverageBuy$36.00Low
8/26/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
8/14/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$29.00 ➝ $36.00Low
8/7/2019CowenSet Price TargetBuy$35.00Medium
5/8/2019MizuhoSet Price TargetHold$27.00Low
5/1/2019CitigroupUpgradeNeutral ➝ Buy$21.00 ➝ $32.00Medium
4/4/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
4/4/2019BMO Capital MarketsBoost Price TargetMarket Perform$29.00Medium
4/2/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Buy$26.00 ➝ $32.00Medium
3/8/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$32.00Low
3/1/2019JMP SecuritiesBoost Price TargetOutperform$26.00 ➝ $38.00High
3/1/2019Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$34.00High
3/1/2019MizuhoReiterated RatingPositive ➝ Neutral$27.00High
2/28/2019CowenSet Price TargetBuy$33.00Medium
2/7/2019MizuhoReiterated RatingHold$21.00Low
1/14/2019Piper Jaffray CompaniesSet Price TargetBuy$26.00Low
11/15/2018MizuhoDowngradeBuy ➝ Neutral$25.00 ➝ $21.00High
11/7/2018MizuhoReiterated RatingBuy$25.00High
11/1/2018Stifel NicolausBoost Price TargetBuy$25.00 ➝ $35.00High
10/23/2018CowenSet Price TargetBuy$25.00High
10/18/2018Cantor FitzgeraldReiterated RatingBuy$21.00Low
10/16/2018MizuhoReiterated RatingBuyHigh
10/6/2018JMP SecuritiesSet Price TargetBuy$22.00High
10/4/2018The Goldman Sachs GroupSet Price TargetBuy$26.00Low
9/24/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00Medium
9/17/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
9/13/2018Cantor FitzgeraldReiterated RatingBuy$21.00Low
8/17/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $24.00Low
8/9/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$21.00 ➝ $23.00High
8/9/2018CowenReiterated RatingBuy$25.00High
8/9/2018Piper Jaffray CompaniesReiterated RatingBuy$25.00High
8/8/2018MizuhoReiterated RatingBuy$18.00High
8/8/2018Cantor FitzgeraldSet Price TargetBuy$21.00Low
8/6/2018BMO Capital MarketsDowngradeOutperform ➝ Market Perform$18.00 ➝ $18.00Low
7/25/2018Cantor FitzgeraldBoost Price TargetOverweight$21.00High
6/27/2018CitigroupDowngradeBuy ➝ NeutralLow
6/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.00Low
5/9/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
5/7/2018MizuhoReiterated RatingBuy$18.00Low
4/15/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
3/14/2018Cantor FitzgeraldReiterated RatingBuy$17.00Low
3/2/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $16.00High
3/1/2018Piper Jaffray CompaniesReiterated RatingBuy$22.00High
3/1/2018CowenReiterated RatingBuy$24.00High
3/1/2018UBS GroupSet Price TargetBuy$20.00Medium
2/28/2018Cantor FitzgeraldSet Price TargetBuy$17.00Medium
1/12/2018MizuhoUpgradeNeutral ➝ Buy$12.00 ➝ $18.00Medium
1/8/2018Cantor FitzgeraldSet Price TargetBuy$17.00Medium
12/27/2017Cantor FitzgeraldSet Price TargetBuy$17.00Low
12/1/2017Cantor FitzgeraldSet Price TargetBuy$17.00Low
11/30/2017UBS GroupSet Price TargetBuy$16.00 ➝ $20.00High
11/7/2017Jefferies Financial GroupBoost Price TargetBuy$16.00 ➝ $21.00N/A
10/22/2017Stifel NicolausReiterated RatingBuy$20.00N/A
10/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00N/A
10/5/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
9/28/2017CowenReiterated RatingBuyLow
9/28/2017The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$16.00Medium
9/27/2017Jefferies Financial GroupReiterated RatingBuy$16.00Medium
9/26/2017Cantor FitzgeraldReiterated RatingBuy$17.00Low
9/11/2017Cantor FitzgeraldReiterated RatingBuy$17.00High
9/10/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00Low
8/28/2017MizuhoReiterated RatingHold$9.00 ➝ $12.00Medium
8/17/2017Cantor FitzgeraldSet Price TargetBuy$17.00Medium
8/10/2017BMO Capital MarketsReiterated RatingOutperform$17.00 ➝ $18.00High
8/9/2017Cantor FitzgeraldReiterated RatingOverweight$13.00 ➝ $17.00High
8/9/2017MizuhoReiterated RatingNeutral$10.00 ➝ $9.00Low
8/8/2017UBS GroupSet Price TargetBuy$16.00High
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00High
7/31/2017Cantor FitzgeraldSet Price TargetBuy$13.00High
7/28/2017BMO Capital MarketsReiterated RatingBuy$17.00High
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$17.00High
7/14/2017Jefferies Financial GroupReiterated RatingBuy$14.00Low
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$13.00Low
6/7/2017UBS GroupSet Price TargetBuy$22.00 ➝ $16.00N/A
5/9/2017CitigroupLower Price TargetBuy$20.00 ➝ $13.00Medium
5/9/2017Jefferies Financial GroupSet Price TargetBuy$26.00 ➝ $14.00Low
5/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$35.00 ➝ $20.00High
5/9/2017CowenSet Price TargetOutperform$42.00 ➝ $20.00Medium
5/9/2017MizuhoDowngradeBuy ➝ Neutral$22.00 ➝ $10.00High
5/9/2017BMO Capital MarketsReiterated RatingBuy$24.00 ➝ $17.00High
4/12/2017Jefferies Financial GroupSet Price TargetBuy$26.00Low
3/29/2017BMO Capital MarketsReiterated RatingBuy$24.00Low
3/24/2017Piper Jaffray CompaniesLower Price TargetOverweight$32.00 ➝ $30.00Low
2/28/2017MizuhoLower Price TargetBuy ➝ Buy$25.00 ➝ $22.00N/A
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/A
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/A
2/22/2017MizuhoReiterated RatingBuy$25.00N/A
12/18/2016Jefferies Financial GroupSet Price TargetBuy$26.00N/A
12/16/2016MizuhoUpgradeNeutral ➝ Buy$14.00 ➝ $25.00N/A
12/9/2016MizuhoDowngradeBuy ➝ Neutral$30.00 ➝ $14.00N/A
12/8/2016UBS GroupSet Price TargetBuy$23.00N/A
12/8/2016Jefferies Financial GroupSet Price TargetBuy$26.00N/A
12/8/2016BMO Capital MarketsReiterated RatingOutperform$29.00 ➝ $24.00N/A
12/1/2016MizuhoReiterated RatingBuyN/A
11/28/2016BMO Capital MarketsReiterated RatingOutperform$29.00N/A
11/28/2016CitigroupUpgradeNeutral ➝ BuyN/A
11/8/2016MizuhoBoost Price TargetBuy$29.00 ➝ $30.00N/A
10/31/2016MizuhoLower Price TargetBuy$33.00 ➝ $29.00N/A
(Data available from 10/19/2016 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/20/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 4 very positive mentions
  • 12 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
10/19/2021

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 6 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Horizon Therapeutics Public logo
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $112.76
Low: $112.67
High: $114.00

50 Day Range

MA: $109.04
Low: $103.19
High: $114.86

52 Week Range

Now: $112.76
Low: $66.41
High: $116.66

Volume

16,081 shs

Average Volume

1,551,421 shs

Market Capitalization

$25.47 billion

P/E Ratio

50.12

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., Maxim Group, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for HZNP.

What is the current price target for Horizon Therapeutics Public?

9 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. Their average twelve-month price target is $119.89, suggesting a possible upside of 6.1%. Morgan Stanley has the highest price target set, predicting HZNP will reach $135.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $100.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.

What is the current consensus analyst rating for Horizon Therapeutics Public?

Horizon Therapeutics Public currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HZNP will outperform the market and that investors should add to their positions of Horizon Therapeutics Public.
View the latest ratings for HZNP.

What other companies compete with Horizon Therapeutics Public?

How do I contact Horizon Therapeutics Public's investor relations team?

Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is (531) 772-2100 and its investor relations email address is [email protected] The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.